Amgen was accused last month of getting special favors from lawmakers. Today the U.S. Supreme Court ruled against it in a securities case that sets precedent for the industry and beyond.
Drugmakers Affymax and Takeda are investigating whether manufacturing is playing a role in the allergic reactions that have resulted in three deaths and led it to recall all of its anemia drug Omontys from the market.
Amgen's earnings last week were not half bad. But they were not good enough to save the jobs of 160 employees whom the company says it will let go.
Congress didn't just head off the fiscal cliff with its compromise bill. It rescued Amgen ($AMGN) from Medicare price restraints on Sensipar, an oral treatment for kidney patients, at least temporarily.
Takeda Pharmaceuticals and Affymax ($AFFY) have sewn up another supply deal for their anemia drug Omontys. DSI Renal, one of the largest dialysis providers in the U.S., agreed to adopt Omontys to treat their patients with chronic kidney disease.
Falling sales of Amgen's ($AMGN) anemia drug Epogen have come home to roost in Longmont, CO, where the company will idle the facility where the drug is made in bulk.
Amgen's big-selling anemia drugs were first brought in for questioning a few years ago. Studies and side-effect reports cast doubt on their safety. The FDA started a review.
The Thousand Oaks, CA-base drugmaker is one of 30 organizations on the docket today for the FDA's informal stakeholder meeting to discuss regulation of biosimilars.
In the years after he took the helm of the company, Rathmann helped steer the development of Epogen and Neupogen. Only now does Amgen face rivals to its anemia franchise.
Affymax has banked a $50 million check from its partner Takeda after they won FDA approval for an anemia treatment that will now compete with Amgen for market share.